To analyze the interaction between empirical therapy and MDR, a variable combining both was introduced in the multivariate analysis. Inappropriate therapy was significantly associated with higher mortality regardless of the susceptibility pattern, and there was a trend toward higher mortality in patients receiving appropriate therapy for MDR than in those appropriately treated for non-MDR strains (OR, 2.2; 95% CI, 0.9 to 5.4). In 47.9% of MDR PAB episodes, appropriate therapy consisted of monotherapy with amikacin. In conclusion, MDR PAB is associated with a higher mortality than non-MDR PAB. This may be related to a higher rate of inappropriate empirical therapy and probably also to amikacin as frequently the only appropriate empirical therapy given to patients with MDR PAB.
P
seudomonas aeruginosa is one of the leading causes of nosocomial bloodstream infections and the third most frequent cause of Gram-negative infections in the United States (31) . This pathogen causes severe infections, especially in immunocompromised hosts, and it is associated with a high mortality rate (29) . In recent years, the number of multidrug-resistant (MDR) strains has increased, and this reduces the probability of administering an appropriate empirical treatment (19) . In critically ill patients with septic shock, every hour of delay in the administration of appropriate antibiotic therapy has been associated with a cumulative increase in the risk of death (11) (12) (13) (14) (15) . Other observations have also supported the importance of appropriate empirical therapy in patients with bacteremia in general (26) or due to particular pathogens, such as methicillin-resistant Staphylococcus aureus (22) or Escherichia coli (21) . For Pseudomonas aeruginosa bacteremia (PAB), previous studies found that inappropriate empirical therapy was a risk factor for mortality when considering all patients (2, 9) or for a subset of patients with more severe infection (8, 27) . However, the influence of multidrug resistance on the probability of receiving appropriate empirical therapy was not evaluated. Some authors have described a higher mortality rate among patients with MDR strains (1, 7, 8, 10, 16, 25, 28) , but these patients more frequently received incorrect empirical therapy and had more severe underlying diseases and longer hospital stays than patients infected by susceptible Pseudomonas aeruginosa strains (24) . Therefore, the individual influence of each one of these variables on the mortality of PAB is still not well defined.
The aim of our study was to determine the influence of appropriate empirical therapy and other important factors, particularly (ii) Definitions. MDR was considered when the strain was resistant to Ն3 antipseudomonal antibiotics (ciprofloxacin, ceftazidime, piperacillintazobactam, meropenem, and amikacin) (6) . Appropriate empirical therapy was considered when the patient received at least one in vitro active antimicrobial agent within 24 h after blood cultures were obtained and before susceptibility results were available and if the dosage and route of administration were in accordance with the current medical standards. Specific dosages of antibiotics were not recorded. However, local guidelines during the study period recommended the administration of aminoglycosides in a single daily dose of 5 to 7 mg/kg of body weight for gentamicin and tobramycin and 15 to 20 mg/kg for amikacin in patients with normal renal function. Sources of infection were grouped according to their mortality risk as follows: (i) low risk (Ͻ15%), urinary tract, vascular catheter, skin and soft tissue, biliary tract, and bone and joint; (ii) intermediate risk (15 to 30%), unknown, abdominal, and other infections (pacemaker infection, endocarditis, and otolaryngology infections); (iii) high risk (Ͼ30%), respiratory.
Microbiological procedures. Antimicrobial susceptibility testing was performed by using a microdilution system (Phoenix system [Becton, Dickinson, Franklin Lakes, NJ] or Etest [AB Biodisk, Solna, Sweden]). Current Clinical and Laboratory Standards Institute (CLSI) breakpoints for each year were used to define susceptibility or resistance to these antimicrobial agents. The antibiotics tested were piperacillin-tazobactam, ceftazidime, cefepime, imipenem, meropenem, ciprofloxacin, gentamicin, tobramycin, amikacin, and colistin. For the purpose of analysis, intermediate susceptibility was considered resistant. Statistical analysis. Data from different groups of patients were compared using chi-square or Fisher's exact tests for categorical variables and the Student t test or Mann-Whitney U test for continuous variables. Patient's characteristics or exposures with a P value of Յ0.20 in the univariate analysis were subjected to further selection by using a forward stepwise nonconditional logistic procedure, and the criteria for variables to step in and out were a P value of 0.10 and 0.10, respectively. A two-tailed P value of Ͻ0.05 was regarded as significant. To evaluate model calibration, the Hosmer-Lemeshow (H-L) test for goodness of fit was applied. Due to the fact that inappropriate empirical therapy was more frequent in MDR PAB, a new variable combining empirical antibiotic therapy and MDR was created to better define the effect of the appropriateness of empirical treatment on mortality. This composite variable was included in the multivariate analysis with four categories, as follows: appropriate therapy and non-MDR (reference category), appropriate therapy and MDR, inappropriate therapy and non-MDR, and inappropriate therapy and MDR. The analysis was carried out using SPSS software (version 17.0; SPSS, Inc., Chicago, IL). Clinical characteristic of patients with MDR and non-MDR PAB are shown in Table 1 . In comparison with non-MDR PAB, MDR PAB episodes were more frequently hospital acquired (85% versus 68%; P Ͻ 0.0001) and were positively associated with a longer hospital stay (31.83 Ϯ 30 days versus 16.38 Ϯ 18 days; P Ͻ 0.0001), bladder catheterization (53.5% versus 37.5%; P Ͻ 0.0001), prior corticosteroid therapy (41.7% versus 33.8%; P ϭ 0.03), prior antibiotic treatment (85.8% versus 53.4%; P Ͻ 0.0001), receipt of inappropriate empirical antibiotic therapy (62.2% versus 27%; P Ͻ 0.0001), and a higher 30-day mortality rate (32.3% versus 17.2%; P Ͻ 0.0001). The specific sources of PAB, the prevalence of MDR for each source, and the 30-day mortality are summarized in Table 2 .
RESULTS

From
A total of 141 (19.9%) patients with PAB died. Factors associated with 30-day mortality in the univariate analysis included an ultimately or rapidly fatal underlying disease (P Ͻ 0.0001), liver cirrhosis (P ϭ 0.02), MDR PAB (P Ͻ 0.0001), mechanical ventilation (P Ͻ 0.0001), septic shock (P Ͻ 0.0001), a high-risk source (P Ͻ 0.0001), and receiving inappropriate empirical antibiotic therapy (P ϭ 0.001) ( Table 3) . In comparison with patients with non-MDR PAB who received appropriate empirical therapy, Table 4 . Factors independently associated with 30-day mortality were age (P ϭ 0.022), septic shock (P Ͻ 0.0001), liver cirrhosis (P ϭ 0.005), an intermediate-risk (P ϭ 0.002) or highrisk (P Ͻ 0.0001) source of infection, and, with use of appropriate empirical therapy in non-MDR PAB as the reference group, receiving inappropriate therapy for non-MDR PAB (OR, 2.18; 95% confidence interval [CI], 1.215 to 3.899; P ϭ 0.009) or receiving inappropriate therapy for MDR PAB (OR, 4.09; 95% CI, 2.156 to 7.778; P Ͻ 0.0001). A nonsignificant trend toward higher mortality in patients with MDR PAB who received appropriate therapy was also observed (P ϭ 0.072). In order to evaluate the quality of empirical therapy, the specific antibiotics administered for MDR PAB were reviewed. The most frequent empirical therapy was monotherapy with amikacin (47.9%), followed by amikacin plus colistin (18.8%), monotherapy with a carbapenem (14.6%), a carbapenem plus amikacin (8.3%), and piperacillin-tazobactam plus amikacin (4.2%). 
DISCUSSION
The 30-day mortality rate for PAB was 19.9%, and this was significantly higher when the infecting strain was MDR (17.2% versus 32.3%; P ϭ 0.0001). Similar to previous published experiences (2, 8, 9, 13, 26, 27) , the analysis of our patients showed an association between mortality and increasing age, patient's comorbidity (liver cirrhosis), shock on presentation, the source of infection (respiratory, unknown, and abdominal sources), and the appropriateness of empirical antibiotic therapy. Among these factors (besides perhaps an earlier and systematic goal-directed approach to maintain tissue perfusion in patients with septic shock), the only factor that could have been improved at the moment of bacteremia clinical presentation was the percentage of patients receiving appropriate empirical therapy. The worldwide increase of MDR in Pseudomonas spp. is directly impacting the proportion of patients adequately treated from the first presentation. Indeed, in our series, inappropriate empirical therapy was significantly more frequent in MDR PAB than in non-MDR PAB (62.2% versus 27%; P ϭ 0.0001).
In general, resistant pathogens are more frequently isolated in patients with poor medical conditions (comorbidity, nosocomial acquisition, previous antimicrobial therapy, prolonged hospitalization), making it difficult to analyze the influence of empirical therapy on the outcome of resistant pathogens. Some authors have identified resistance to ceftazidime, carbapenems, or MDR as risk factors for mortality (1, 7, 16, 24, 25, 28) . In contrast, Combes et al. (3) evaluated the impact of piperacillin resistance on the outcomes of P. aeruginosa ventilator-associated pneumonia in patients who received appropriate empirical antibiotics, and they found that piperacillin resistance was not associated with higher mortality. These results suggest the importance of adjusting for appropriate empirical antibiotic to clarify the influence of resistance on mortality. The present large series of PAB with an MDR prevalence of 17.9% allowed us to perform the analysis of the influence of both MDR and appropriateness of empirical therapy on the mortality of PAB. Since there was an interaction between MDR and receiving inappropriate empirical therapy, a variable combining both was included in the logistic regression analysis. Compared with appropriate therapy in non-MDR episodes, inappropriate therapy in non-MDR PAB (OR, 2.18; 95% CI, 1.215 to 3.899; P ϭ 0.009) and inappropriate therapy in MDR PAB (OR, 4.09; 95% CI, 2.156 to 7.778; P Ͻ 0.0001) were associated with higher mortality. However, the observed nonsignificant trend toward higher mortality in patients with MD PAB who received appropriate therapy suggests an intrinsic influence of MDR on prognosis. This cannot be entirely discarded, since some virulence traits, such as the secretion of type III exotoxins by P. aeruginosa, have been independently associated with poor prognosis in patients with bacteremia, and this trait is, in turn, more prevalent in strains resistant to ciprofloxacin, cefepime, and gentamicin (5). An alternative explanation for that trend may lie in the fact that, in our center, MDR P. aeruginosa is in general only susceptible to amikacin and colistin. Therefore, in the present study appropriate empirical therapy for many cases of MDR PAB (47.9%) consisted of monotherapy with amikacin. According to previous clinical experiences, single-aminoglycoside therapy may be a suboptimal treatment (18, 23, 30) , except for urinary tract infections. Although every effort should be made to administer aminoglycosides in a manner directed to achieve an optimal ratio of the maximal drug concentration in the serum versus the MIC (as a rule, in a high single daily dose) (4, 17) , it is not clear whether this approach can overcome the apparent suboptimal efficacy of aminoglycosides as single agents and, certainly, the risk of nephrotoxicity is still of concern.
The present study has some limitations. First, the potential influences of different antibiotics or of combination therapies were not evaluated. Second, MIC values and specific dosages of antibiotics were not recorded; hence, we cannot evaluate the influence of pharmacokinetics-pharmacodynamics parameters. Lastly, despite use of multivariate analysis, inadequate control for confounding by comorbid illness cannot be completely discarded. However, this is the largest series of PAB with a high prevalence of MDR that has demonstrated the importance of appropriate empirical therapy.
In conclusion, the mortality for P. aeruginosa infection and the prevalence of MDR strains were high. MDR PAB had a higher 30-day mortality than non-MDR PAB, and according to our analysis this was due to a higher rate of inappropriate empirical antibiotic therapy and because in almost 50% of MDR PAB episodes appropriate empirical therapy consisted of monotherapy with amikacin. These findings strengthen the needs for revision of the empirical regimens for patients at risk of MDR PAB and of developing new antipseudomonal antibiotics.
